Cellular Biomedicine Group "Stock News Now" Video Interview Now Available Online
February 04 2015 - 8:00AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective stem cell therapies for degenerative diseases and
immunotherapies for cancer, today announced that an interview with
Dr. William (Wei) Cao, Chief Executive Officer for the Company,
conducted by Stock News Now (SNN Incorporated) at last month's J.P.
Morgan Healthcare Conference in San Francisco, is now available
online.
The interview provides an overview of the Company's immune cell
therapy platform focused on oncology and its Phase II clinical
trial for Knee Osteoarthritis (KOA), which is differentiated by its
use of the patient's own fat tissue. Also highlighted are the
Company's impressive IP portfolio and its outlook for 2015 and
2016. "We look forward to acquiring more technology and
partnerships in order to fortify our IP portfolio in 2015, and to
announcing the interim results from our KOA Phase IIb clinical
trial in the first quarter of 2015 and the full results from our
KOA Phase IIb clinical trial in early 2016," said Dr. Cao.
The interview may be viewed online at:
https://www.youtube.com/watch?v=DUWan26oF6k or on the Stock News
Now website, www.stocknewsnow.com.
About SNN Incorporated
SNN Incorporated is a global multimedia financial news and
publishing company that focuses on market awareness and investor
visibility for public and private micro-cap companies. The Company
publishes StockNewsNow.com, MicroCap Review Magazine, and
co-produces the Growth Capital Expo.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United States. Our
flagship GMP facility, consisting of eight independent cell
production lines, is designed, certified and managed according to
U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024